WWC
GOSS icon

Waypoint Wealth Counsel’s Gossamer Bio GOSS Stock Holding History

Waypoint Wealth Counsel’s Portfolio GOSS Stock Details GOSS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-11,758
Closed -$10.7K – 102
2023
Q4 		$10.7K Buy
11,758
+300
+3% +$222 0.01% 98
2023
Q3 		$9.54K Buy
+11,458
New +$13.2K 0.01% 91

Other funds holding GOSS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Waypoint Wealth Counsel's GOSS Position: Q1 2024 in Review

Waypoint Wealth Counsel sold out of Gossamer Bio (GOSS) in Q1 2024, closing a stake of 11,758 shares — an estimated $10.7K sold.

Waypoint Wealth Counsel first reported a position in GOSS in Q3 2023 and held it in 2 quarters. The position peaked at $10.7K in Q4 2023. 110 funds tracked by Wall St. Rank hold GOSS as of Q1 2024.

  • Waypoint Wealth Counsel reported no remaining Gossamer Bio position as of Q1 2024 after selling out during the quarter.
  • Waypoint Wealth Counsel sold 11,758 Gossamer Bio shares in Q1 2024, an estimated $10.7K.
  • Waypoint Wealth Counsel first reported a position in Gossamer Bio in Q3 2023 and held it in 2 quarters.
  • Waypoint Wealth Counsel's Gossamer Bio position peaked at $10.7K in Q4 2023.
  • 110 funds tracked by Wall St. Rank held Gossamer Bio as of Q1 2024.

Based on Waypoint Wealth Counsel's 13F filing for Q1 2024, filed 12 Apr 2024.